Open House - Global Healthcare 2022: VolitionRx Limited | Edison Group
VolitionRx Limited manufactures epigenetic cancer detection blood tests. The Company’s tests are designed to detect the nucleosome patterns that are specific to cancer in the blood and identify some of the major nucleosome varieties that differ between cancer types.
-
Cameron Reynolds, President and Group Chief Executive Officer, Volition
Cameron is the President and Group Chief Executive Officer of Volition and was one of the founders of the company in 2010. He is an experienced entrepreneurial executive, with expertise in a wide range of fields, including several biotechnology companies and has led Volition through the research and development of Volition’s proprietary Nucleosomics™ to the commercialization of its first test, the Nu.Q™ Vet Cancer Screening Test. Cameron has extensive experience in the management, structuring, and financing of start-up companies and has held positions including Chief Executive Officer, Chief Financial Officer, Chairman, and Non-Executive Director of public and private enterprises. Cameron was educated at the University of Western Australia receiving both a Bachelor of Commerce and an MBA.
